Tag Archives: EPA Registered Products

Making a Difference – Innovations in Infection Prevention 2020 Awards

Awards Announcement:

Making a Difference – Innovations in Infection Prevention 2020

C Diff Foundation acknowledges the following organizations “Making a Difference”
In the Infection Prevention community, with their innovative products, services, and
technologies addressing infection prevention.

 

 

 

 

Applied Silver
Innovation: SilvaClean® Technology
SilvaClean chemistry is EPA-approved as a laundry additive with residual activity
against post-laundry contamination.
The SilvaClean system is a dispensing device enabled by the Internet of Things (IoT)
that doses the EPA-approved SilvaClean chemistry onto textiles, leaving fabrics with
residual antimicrobial properties even after laundering (e.g. in storage, during handling
and in use).
http://www.appliedsilver.com/

 

 

 

 

Intellego Technologies
Innovation: UVC Dosimeter
Able to measure specific wavelengths of UVC radiation.
Can be correlated with a log reduction of microbiology samples e.g. MRSA and C. diff.
Proven functionality through hospital testing.
http://intellego-technologies.com/

 

 

 

 

Synexis Biodefense Systems
Innovation: Synexis Microorganism Reduction Systems
Patented Dry Hydrogen Peroxide (DHP) technology uses a building’s ambient humidity
and oxygen to continuously achieve sustainable reduction of microbial challenges from
viruses, bacteria, and mold in the air and on workplace surfaces.
DHP technology is inexpensive, highly scalable, and can be installed standalone or in
existing HVAC systems.
https://synexis.com/

Join Us in November!

Join Us at the 8th Annual International C. diff. Conference and Health EXPO taking
place in Boston, Massachusetts USA on November 12th and 13th, 2020 where we will
present and showcase these prestigious awards to the 2020 “Making a Difference” Innovations In Infection Prevention organizations.

Early Bird Registration is in progress — save over 20% until June 2020.

Congratulations to the organizations dedicated in preventing infections and for
developing products, services, and technology capable to ward off harmful bacteria in
all areas of health care and commercial environments. We are truly grateful for the
innovative measures taken to accomplish this goal.

 

 

C Diff Foundation, a 501(c) (3) non-profit organization, established in 2012, and
comprised of 100% volunteering professionals dedicated at supporting public health
through education and advocating for C. difficile infection (CDI) prevention, treatments,
clinical trials, diagnostics, and environmental safety worldwide.

 

(Disclaimer: C Diff Foundation declares no conflict of interest; no funds or influence
were provided to C Diff Foundation by any parties.)

 

U.S. Environmental Protection Agency (EPA) Announced Methods and Guidance for Evaluating Efficacy of Antimicrobial Products against Clostridium difficile Spores

 

On September 29, 2017, the U.S. Environmental Protection Agency (EPA) announced the availability of two final test method Standard Operating Procedures (SOP) for evaluating the efficacy of antimicrobial products against  Clostridium difficile (C. diff) spores.

EPA also released regulatory guidance for test criteria and pesticide claims for these products, specifically “Methods and Guidance for Testing the Efficacy of Antimicrobial Products Against Spores of Clostridium difficile on Hard Non-Porous Surfaces.”  These test methods and guidance provide a framework for registrants who seek to make a claim for antimicrobial pesticide products to control these spores on hard, non-porous surfaces.

C. diff is an anaerobic, spore-forming bacterium and a  leading hospital-acquired infection.  The spores survive on hard surfaces such as glass, metals, and plastics that are commonly found in health-care settings.

Antimicrobial pesticides are used to reduce the number of spores on environmental surfaces.  Under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), the registrant of an antimicrobial product with a public health claim is required to submit efficacy data to EPA in support of the product’s registration.

EPA MLB SOP MB-28 describes the test methodology for producing and storing standardized spore suspensions of C. diff based on ASTM E2839, Standard Test Method for Production of C. difficile Spores for Use in Efficacy Evaluation of Antimicrobial Agents (ASTM International).  A spore suspension should be developed and qualified according to EPA MLB SOP MB-28 before an efficacy evaluation can be performed using method EPA MLB SOP MB-31.  EPA MLB SOP MB-31 describes a quantitative method intended for evaluating the sporicidal efficacy of liquid disinfectants against spores of C. diff on inanimate, hard, non-porous surfaces.

EPA solicited comments on the clarity of the test method SOPs and the regulatory guidance in December 2016.  EPA received comments from twelve entities and revised the drafts to incorporate suggested changes.  EPA posted its response to those comments in Docket No. EPA-HQ-OPP-2016-0753-0026.  EPA also is working with ASTM International, a standard-setting organization, on adoption of these test methods as official ASTM standards.

EPA’s response to comments and other documents associated with this action are available in Docket No. EPA-HQ-OPP-2016-0753 at www.regulations.gov

The methods and guidance also are found on EPA’s Antimicrobial Testing Methods & Procedures Developed by EPA’s Microbiology Laboratory webpage, at the Methods tab as Method IDs MB-28 and MB-31, and at the Guidance tab as Sporicidal Claims Against Clostridium difficile.

 

Source:  https://www.natlawreview.com/article/methods-and-guidance-testing-efficacy-antimicrobials-against-spores-clostridium